CSIMarket Company Name, Ticker, Competitors, else..
 
Minerva Neurosciences Inc   (NASDAQ: NERV)
Other Ticker:  
 
 
Price: $1.8500 $0.00 0.000%
Day's High: $1.87 Week Perf: 9.14 %
Day's Low: $ 1.82 30 Day Perf: 3.35 %
Volume (M): 5 52 Wk High: $ 3.69
Volume (M$): $ 10 52 Wk Avg: $2.51
Open: $1.87 52 Wk Low: $1.42



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 8
 Employees 21
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 0

Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for central nervous system (CNS) disorders. The company's main objective is to deliver new treatment options to individuals suffering from diseases such as schizophrenia, major depressive disorder, insomnia, and Parkinson's disease.

Through their extensive research and development efforts, Minerva Neurosciences aims to identify and advance novel drug candidates that target the underlying neurobiology of these CNS disorders. They leverage their expertise in preclinical and clinical development, as well as neuropharmacology, to design and execute clinical trials that assess the safety and efficacy of their potential therapies.

Minerva Neurosciences has a diverse pipeline of product candidates, including MIN-101, which is being developed for the treatment of negative symptoms of schizophrenia, and MIN-202, a potential therapy for insomnia disorder. The company also has collaborative research programs with other biopharmaceutical companies and academic institutions to explore additional treatment options for CNS disorders.

As a clinical-stage company, Minerva Neurosciences is focused on advancing their product candidates through various clinical trial phases to ultimately obtain regulatory approvals and bring their therapies to market. They are committed to improving the lives of patients suffering from CNS disorders through the development of innovative and effective treatments.


   Company Address: 1500 District Avenue Burlington 1803 MA
   Company Phone Number: 600-7373   Stock Exchange / Ticker: NASDAQ NERV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ITCI        0.06% 
NGNE   -7.91%    
OKUR   -4.4%    
QURE        2.28% 
SAGE        5.83% 
TRDA   -5.48%    
• View Complete Report
   



Product Service News

Minerva Neurosciences Receives Unexpected Regulatory Setback as FDA Issues Complete Response Letter for Innovative Schizophrenia Treatment

Published Tue, Feb 27 2024 1:01 PM UTC

BURLINGTON, Mass., Feb. 27, 2024 - Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, has recently encountered a hurdle in its pursuit of advancements in schizophrenia treatment. The U.S. Food and Drug Administration (FDA) has issued a Complete Response Lett...
Minerva Neurosciences Inc

Minerva Neurosciences Inc Faces Mounting Challenges as Operating Deficit Deepens in Q3 2023



In a surprising turn of events, the Major Pharmaceutical Preparations industry is closely observing the financial results of Minerva Neurosciences Inc's third quarter of 2023 earnings. With no mention of revenue yet, experts within the industry are trying to decipher the implications of the company's operating deficit of $-6.07912 million. These numbers present a significant decrease compared to the same quarter in 2022, where the deficit stood at $-5.207148 million. However, analysts are now speculating when Minerva Neurosciences Inc will finally start to report revenue.
A Deepening Operating Deficit:
One of the key takeaways from the financial reporting period spanning July to September 30, 2023, is the $-7.820 million shortfall. This figure represents a worrisome increase from the $-6.900 million loss reported in the third quarter of 2022. While operating deficits are not uncommon in the pharmaceutical industry as research and development costs are high, the intensification of this loss raises concerns among investors and industry insiders alike.
Minerva Neurosciences Inc

Minerva Neurosciences Inc Reports Promising Progress; Q2 2023 Operating Deficit Narrows to $-6.965189 Million Amid Unchanged Top-Line Expectations

As a stock market journalist, it is my duty to interpret the financial results of companies and provide insights for investors. In this article, I will be examining the recent financial results of Minerva Neurosciences Inc and commenting on the changes in its stock performance.
Looking at the company's financial reports for the April to June 30, 2023 reporting cycle, it is evident that there haven't been any significant modifications at the top-line. Investors were likely hoping for some positive changes in this area, but unfortunately, that did not materialize.
Minerva Neurosciences Inc

Surprising Turnaround: Minerva Neurosciences Inc Slashes Operating Loss in First Quarter and Leaves Investors Excited for Future Growth

In recent financial news, investors were caught off-guard by some changes at Minerva Neurosciences Inc during the January to March 31, 2023 reporting season. Despite this, they were pleased to observe that the company's operating loss had decreased significantly, coming in at $-5.348518 million during the same period. This represents a positive change compared to the first quarter of 2022, when the company's operating loss stood at $-7.989258 million.
As an emerging growth company, it is important for Minerva Neurosciences to continue developing business strategies and competing effectively within its market. The positive changes observed during this reporting season offer a promising sign for the company's future growth potential. Although there is still room for improvement, the fact that Minerva Neurosciences managed to reduce its operating loss in just one year is commendableOne major takeaway from the financial period ending March 31, 2023 is that there has been some relief on the net loss front. The company's deficit was significantly reduced from the same time frame a year ago, with the deficit coming in at $-6.970 million, down from $-9.764 million during the first quarter of 2022.
Overall, Minerva Neurosciences Inc has made some positive strides during the January to March 31, 2023 reporting season. Investors will be watching closely for further developments and are eagerly anticipating the company's next financial earnings report, which is expected to be released on August 08, 2023.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com